HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch

ACP Names Semaglutide, Tirzepatide as First-Line Pharmacotherapy for Obesity

ACP Names Semaglutide, Tirzepatide as First-Line Pharmacotherapy for Obesity

By AJMC · Jun 15, 2026 · via AJMC

This is an aggregated industry headline. Read the full story at AJMC

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlineAJMC
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Following criticism from drugmakers, Germany has scrapped its plan to install a program that would have reduce…
Jun 16, 2026
Spyre spies another edge for UC ambitions with midstage win for anti-TL1A antibody
The WeekFierceBiotech ↗
The company's SPY002 prompted a 10.7-point reduction from baseline levels in patients' Robart's Histopathology…
Jun 16, 2026
FDA clears Colorado drug import plan from Canada
The WeekBriefing
The FDA approved Colorado’s proposal to import certain Canadian drugs, aiming to curb costs for state resident…
Jun 16, 2026